FMC Secures $200M Upfront Payment from Corteva for Breakthrough Herbicide Partnership
FMC is trading near its 52-week low of $10.715 (8.3% above the low).
Summary
FMC Corporation and Corteva, Inc. have entered a co-exclusive strategic supply and license agreement for FMC's rimisoxafen herbicide technology, with Corteva making a $200 million upfront payment to FMC. This partnership expands access to the breakthrough dual mode of action herbicide across North and South American corn and soybean markets, addressing critical herbicide-resistant weed challenges. The $200 million payment is a significant cash inflow for FMC, especially following its substantial first-quarter loss reported in late April. Both companies will commercialize their own formulations, with first sales anticipated by the end of the decade, pending regulatory approvals.
At the time of this announcement, FMC was trading at $11.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $10.72 to $44.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.